Cannabidiol does not cause DNA double-strand breaks in a human liver-derived cell model

Area of Science:

• Pharmacology
• Cell Biology
• Toxicology

Background:

• Cannabidiol (CBD) exhibits therapeutic potential but raises concerns regarding DNA damage.
• Previous studies on CBD's genotoxicity used cell lines that may not accurately represent human liver metabolism.
• Investigating CBD's effects on DNA double-strand breaks (DSBs) and proliferation in HepG2 cells is crucial.

Purpose of the Study:

• To assess the impact of short-term CBD exposure on DNA DSBs in human liver cells (HepG2).
• To evaluate the effect of CBD on HepG2 cell proliferation and cannabinoid receptor expression.
• To determine if CBD induces genotoxicity in a relevant liver cell model.

Main Methods:

• HepG2 cells were treated with varying concentrations of CBD (5-50 µg/mL) for 3-72 hours.
• Western blot analysis was used to examine cannabinoid receptor 1 (CB1) and 2 (CB2) expression.
• DNA DSBs were detected using γH2AX and 53BP1 foci assays, with Etoposide as a positive control.

Main Results:

• CBD downregulated CB2 receptor expression in a dose-dependent manner.
• No significant increase in DNA DSBs (γH2AX and 53BP1 foci) was observed following CBD treatment.
• CBD treatment led to a significant reduction in HepG2 cell proliferation.

Conclusions:

• CBD modulates CB2 expression and increases intracellular cAMP in HepG2 cells, suggesting a stimulatory effect.
• CBD at concentrations of 5-50 µg/mL does not significantly induce DNA DSBs in HepG2 cells.
• CBD significantly reduces cell proliferation and increases intracellular cAMP levels in HepG2 cells.